Genotoxicity assay to identify carcinogenic agents
CompanyPrediTox, Toulouse, France
To identify potential cancer-causing agents, the company PrediTox has developed the PrediScreen genotoxicity assay. The technology is based on a study of the biomarkers H2AX (γH2AX) and H3 (pH3). The test is therefore able to reliably distinguish genotoxic (aneugenic and clastogenic) compounds from cytotoxic compounds. In addition, PrediScreen provides important information on the metabolic bioactivity of the active ingredients to be examined and shows a more sensitive measure of viability than the classic MTT assay. The proof of concept of the method was carried out on compounds recommended by ECVAM for the validation of alternative methods. Through the combined assessment of relevant genotoxic biomarkers, the PrediScreen provides more comprehensive information than previous established assays. In summary, the test optimizes toxicology screening and the safety assessment of new drugs and can help reduce drug-induced damage and improve the development of relevant (cancer) therapeutics.
Genotoxicity assay
contact@preditox.fr
Added on: 10-18-2023
[1] http://preditox.fr/en/service/genotoxicity-assay/
